Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing.
Wang Z, Dove P, Wang X, Shamas-Din A, Li Z, Nachman A, Oh YJ, Hurren R, Ruschak A, Climie S, Press B, Griffin C, Undzys E, Aman A, Al-awar R, Kay LE, O'Neill D, Trudel S, Slassi M, Schimmer AD. Wang Z, et al. Among authors: shamas din a. Cell Death Dis. 2015 Jul 9;6(7):e1815. doi: 10.1038/cddis.2015.187. Cell Death Dis. 2015. PMID: 26158521 Free PMC article.
Drug discovery in academia.
Shamas-Din A, Schimmer AD. Shamas-Din A, et al. Exp Hematol. 2015 Aug;43(8):713-7. doi: 10.1016/j.exphem.2015.02.007. Epub 2015 Apr 23. Exp Hematol. 2015. PMID: 25912018 Free article. Review.
A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia.
Reed GA, Schiller GJ, Kambhampati S, Tallman MS, Douer D, Minden MD, Yee KW, Gupta V, Brandwein J, Jitkova Y, Gronda M, Hurren R, Shamas-Din A, Schuh AC, Schimmer AD. Reed GA, et al. Among authors: shamas din a. Cancer Med. 2016 Nov;5(11):3031-3040. doi: 10.1002/cam4.845. Epub 2016 Oct 13. Cancer Med. 2016. PMID: 27734609 Free PMC article. Clinical Trial.
Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML.
Liyanage SU, Hurren R, Voisin V, Bridon G, Wang X, Xu C, MacLean N, Siriwardena TP, Gronda M, Yehudai D, Sriskanthadevan S, Avizonis D, Shamas-Din A, Minden MD, Bader GD, Laposa R, Schimmer AD. Liyanage SU, et al. Among authors: shamas din a. Blood. 2017 May 11;129(19):2657-2666. doi: 10.1182/blood-2016-10-741207. Epub 2017 Mar 10. Blood. 2017. PMID: 28283480 Free PMC article.
A phase I study of elesclomol sodium in patients with acute myeloid leukemia.
Hedley D, Shamas-Din A, Chow S, Sanfelice D, Schuh AC, Brandwein JM, Seftel MD, Gupta V, Yee KW, Schimmer AD. Hedley D, et al. Among authors: shamas din a. Leuk Lymphoma. 2016 Oct;57(10):2437-40. doi: 10.3109/10428194.2016.1138293. Epub 2016 Feb 5. Leuk Lymphoma. 2016. PMID: 26732437 Clinical Trial. No abstract available.
18 results